LONDON - Galapagos NV cemented its reputation as a drug discovery partner of choice for big pharma, signing a potential €400 million (US$579.6 million) deal with F. Hoffmann-La Roche Ltd. in both small-molecule and antibody treatments for chronic obstructive pulmonary disease (COPD). (BioWorld International) BioWorld International Correspondent Read More
No Abstract BioWorld International Correspondent Adocia SA raised €14 million (US$20.3 million) in a second funding round to continue development of its BioChaperone protein delivery technology, which is designed to prolong the localized activity of growth factors and other protein-based drugs at their sites of action. The company, based in Lyon, France, has filed investigational new drug applications on its first two development programs, and clinical trials are due to begin shortly. Read More
